Calliditas Therapeutics A... (CALT)
NASDAQ: CALT
· Real-Time Price · USD
40.00
-0.04 (-0.10%)
At close: Sep 20, 2024, 10:00 PM
Calliditas Therapeutics AB (publ) Income Statement
Financials in SEK. Fiscal
year is
January - December.
| Fiscal Year | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 1.6B | 1.31B | 1.21B | 1.18B | 1.15B | 944.5M | 802.88M | 405.02M | 343.13M | 279.08M | 229.35M | 198.57M | 400K | 400K |
Cost of Revenue | 104.68M | 65.45M | 60.46M | 46.04M | 35.44M | 23.61M | 15.2M | 7.32M | 3M | 614K | n/a | n/a | n/a | n/a |
Gross Profit | 1.5B | 1.25B | 1.15B | 1.14B | 1.11B | 920.88M | 787.68M | 397.7M | 340.13M | 278.47M | 229.35M | 198.57M | 400K | 400K |
Operating Income | -368.18M | -409.15M | -389.43M | -341.49M | -218.15M | -352.82M | -383.22M | -682.71M | -638.62M | -588.18M | -524.46M | -438.26M | -551.01M | -458.18M |
Interest Income | 16.16M | 20.68M | 48.62M | 96.65M | 116.92M | 130.16M | 102.22M | 52.45M | 32.18M | 14.42M | 29.03M | 14.61M | 14.61M | 19.91M |
Pretax Income | -468.32M | -496.32M | -457.02M | -432.69M | -284.57M | -406M | -409.42M | -637.95M | -615.51M | -588.63M | -513.37M | -468.18M | -612.6M | -508.65M |
Net Income | -480.36M | -524.82M | -466.18M | -451.5M | -292.25M | -392.75M | -412.27M | -627.76M | -612.2M | -579.61M | -498.02M | -449.28M | -593.75M | -495.23M |
Selling & General & Admin | 1.31B | 1.16B | 1.06B | 1.04B | 968.45M | 872M | 774.66M | 653.46M | 561.69M | 473.88M | 390.23M | 302.4M | 248.07M | 182.49M |
Research & Development | 557.91M | 526.18M | 502.22M | 497.78M | 420.75M | 428.06M | 414.75M | 412.8M | 402.02M | 380.75M | 357.49M | 331.19M | 303.98M | 277.34M |
Other Expenses | n/a | n/a | n/a | 13.51M | 15.46M | 18.5M | 20.21M | 8.01M | 8.9M | 5.87M | 6.08M | 5.74M | 1.87M | 1.24M |
Operating Expenses | 1.86B | 1.65B | 1.54B | 1.52B | 1.38B | 1.32B | 1.21B | 1.07B | 972.62M | 860.51M | 753.8M | 636.83M | 551.41M | 458.57M |
Interest Expense | 59.16M | 48.01M | 32.45M | 32.45M | 48.21M | 65.97M | 41.09M | 41.09M | 22.2M | 4.44M | 1.38M | 1.38M | n/a | n/a |
Selling & Marketing Expenses | 862.18M | 800.66M | 727.74M | 721.09M | 666.72M | 588.52M | 515.19M | 393.94M | 308.98M | 254.07M | 179.6M | 95M | 63.83M | 5.46M |
Cost & Expenses | 1.97B | 1.72B | 1.6B | 1.57B | 1.41B | 1.34B | 1.22B | 1.08B | 975.62M | 861.12M | 753.8M | 636.83M | 551.41M | 458.57M |
Income Tax Expense | 12.04M | 28.5M | 9.17M | 18.8M | 7.68M | -13.26M | 2.85M | -10.7M | -3.82M | -6.3M | -11.21M | -11.24M | -11.19M | -8.98M |
Shares Outstanding (Basic) | 26.84M | 13.42M | 26.84M | 26.84M | 26.84M | 26.84M | 26.63M | 13.31M | 13.3M | 13.1M | 13.09M | 12.77M | 12.49M | 12.49M |
Shares Outstanding (Diluted) | 26.84M | 13.42M | 26.84M | 26.84M | 26.84M | 26.84M | 26.63M | 13.31M | 13.3M | 13.1M | 13.09M | 12.89M | 12.49M | 12.49M |
EPS (Basic) | -27.06 | -28.72 | -17.36 | -16.82 | -11.22 | -22.28 | -31.12 | -47.72 | -46.54 | -44.86 | -39.08 | -36 | -47.58 | -40.78 |
EPS (Diluted) | -27.06 | -28.72 | -17.36 | -16.82 | -11.22 | -22.28 | -31.12 | -47.72 | -46.54 | -44.86 | -39.08 | -36 | -47.58 | -40.78 |
EBITDA | -362.31M | -405.98M | -383.29M | -336.48M | -213.47M | -348.15M | -376.44M | -658.19M | -614.29M | -563.83M | -506.24M | -440.73M | -553.47M | -460.64M |
EBIT | -363.9M | -407.57M | -383.82M | -337M | -213.66M | -348.33M | -376.62M | -658.38M | -614.3M | -563.85M | -506.27M | -494.3M | -607.05M | -514.21M |
Depreciation & Amortization | 5.34M | 3.17M | 2.64M | 2.11M | 1.77M | 1.43M | 1.09M | 747K | 569.5K | 392K | 214.5K | 37K | 38.75K | 40.5K |